decisionhealth Newsletters, Part B News - 2002 Issue 12 (December)
Inherent reasonableness rule could lead to lower drug payments
Subscribe or sign in to view the full article.
Article Overview
This article discusses a federal interim final rule that changes how CMS may review and adjust payment amounts for certain Medicare Part B-related items and services. It is aimed at readers who follow medical reimbursement policy, especially physicians, oncology practices, pharmacies, durable medical equipment suppliers, and billing staff. The piece covers the rule’s effective date, the types of services it may affect, the administrative process CMS says it will follow, and concerns raised by providers and industry representatives.
Why This Topic Matters
The rule may affect reimbursement levels for selected drugs and other services, which can influence practice economics, supplier pricing, and payer policy monitoring. Understanding the scope of the change helps stakeholders assess potential financial and operational impact.
What You Will Learn
- What the CMS interim final rule is about
- Which broad categories of Medicare payments may be affected
- How the public comment process is described
- What concerns stakeholders raise about reimbursement changes
- How CMS frames its authority and oversight approach
Who Should Read This
- Physicians
- Oncology practices
- Medical billers and coders
- Practice managers
- Durable medical equipment suppliers
- Health care attorneys
- Pharmaceutical reimbursement specialists
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com